Αρχική World News Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients... World News Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma Από Ogkologos - 24 Οκτωβρίου, 2025 428 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide 5 Δεκεμβρίου, 2025 Prostate cancer: Lessons Learned from My Breast Cancer 23 Ιουνίου, 2021 Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... 4 Οκτωβρίου, 2021 Five Questions With…Stephen. 5 Μαΐου, 2022 Φόρτωση περισσοτέρων HOT NEWS Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... NICE doesn’t recommend olaparib for patients with certain prostate cancers Man With Cancer Receives $15,000 Check From ‘Secret Santa’ To Help... EMA Recommends Granting a Marketing Authorisation for Mirvetuximab Soravtansine